Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection

Author's Avatar
Dec 01, 2022

Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe%3Csup%3E%26reg%3B%3C%2Fsup%3E+Nexus+200%26trade%3B, expanding its robust endotoxin testing portfolio. The Nexus 200 is the next evolution of Charles River’s data integrity compliant, fully robotic instrument, capable of processing both undiluted or complex, serial dilutions for water, in-process, and final product testing via Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology in a fully enclosed system. Powered by Endosafe EndoScan-V version 6.1, the system allows for data to be exported into a Laboratory Information Management System (LIMS) integration and provides improved traceability, security, and data management on an integrated touch screen.